Publication:
PROFIT WINDFALL OR PATIENT WINDFALL? The Orphan Drug Act and Proposals for its Reform

Thumbnail Image

Date

1994

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

PROFIT WINDFALL OR PATIENT WINDFALL? The Orphan Drug Act and Proposals for its Reform (1994 Third Year Paper)

Research Data

Abstract

The Orphan Drug Act is a statute with a noble purpose but a controversial history. Originally designed to spur research into drugs for conditions with extremely limited patient populations,~ the Act has become a highly successful means of developing new drugs for rare diseases and conditions. In total, these conditions affect a significant percentage of the population -- as many as 1 out of every 13 Americans. In the ten years prior to the Act's passage, only ten drugs had been approved for these conditions, but by December 31, 1993, 569 drugs had received designation as orphan drugs under the Act; of these, over 65 had been approved. Few, then, would dispute that for its intended purpose -- benefit to patients suffering from rare conditions -- the Act has worked successfully.

Description

Other Available Sources

Keywords

Food and Drug Law, Orphan Drug Act, human growth hormone, erythropoietin, EPO, pentamidine, Genentech

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories